SCHEMBL23995261

SCHEMBL23995261

C[C@H]1C[C@@H]1c1ccc2cnn(CC(F)(F)F)c2c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KCNJ6 P48051 6/20 0.36
▸ KCNJ5 P48544 6/20 0.36
▸ KCNJ3 P48549 6/20 0.36
▸ HTR2A P28223 5/20 0.36
▸ HTR2C P28335 5/20 0.36
▸ HTR2B P41595 4/20 0.34
▸ HTR1A P08908 2/20 0.34
▸ ADRA2A P08913 2/20 0.34
▸ ADRA2B P18089 2/20 0.34
▸ ADRA2C P18825 2/20 0.34
▸ HTR1D P28221 1/20 0.34
▸ HTR7 P34969 1/20 0.34
▸ HTR4 Q13639 1/20 0.34
▸ KMO O15229 3/20 0.33
▸ CHRM2 P08172 3/20 0.32
▸ CHRM1 P11229 3/20 0.32
▸ CHRM3 P20309 3/20 0.32
▸ BRD4 O60885 1/20 0.32
▸ PDE2A O00408 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25006021 0.87 HTR2A (0.38) KCNJ6KCNJ5KCNJ3HTR2AHTR2C
SCHEMBL23995200 0.86 HTR2C (0.34) HTR2AHTR2CHTR2BHTR1AADRA2A
SCHEMBL23994564 0.85 HTR2A (0.39) HTR2AHTR2CHTR2BHTR1AADRA2A
SCHEMBL25589567 0.84 HTR2A (0.32) HTR2AHTR2CHTR2BKMO
SCHEMBL30224760 0.80 HTR2A (0.31) HTR2AHTR2CHTR2B
SCHEMBL25004502 0.80 HTR2A (0.35) HTR2AHTR2CHTR2BHTR1AADRA2A
SCHEMBL23995368 0.79 KCNJ6 (0.39) KCNJ6KCNJ5KCNJ3
SCHEMBL23994569 0.79 KCNJ6 (0.34) KCNJ6KCNJ5KCNJ3
SCHEMBL25004360 0.78 CYP17A1 (0.36) KCNJ6KCNJ5KCNJ3PDE2A
SCHEMBL23995447 0.77 KCNJ6 (0.37) KCNJ6KCNJ5KCNJ3PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021222522-A1 CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS GILEAD SCIENCES, INC. (US) 2021-11-04 — — WO disclosed
Send feedback